RecruitingPhase 3NCT03647072
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.
Sponsor
Sherief Abd-Elsalam
Enrollment
60 participants
Start Date
Aug 1, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- DLBCL Lymphoma subtype --No comorbid disease
Exclusion Criteria4
- Pregnancy
- Peptic ulcer
- Severe cardiac disease
- Osteoporosis
Interventions
DRUGCHOP
CHOP only
DRUGCHOP Plus Lanzoprazole
CHOP plus Lanzoprazole 60 mg
DRUGCHOP Plus Famotidine
CHOP Plus Famotidine 40 mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03647072
Related Trials
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT0233266817 locations
Odronextamab in Low Tumor Volume Advanced FL
NCT071286411 location
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT065103613 locations
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
NCT052943671 location